womenage 55-64 y.o.3%HepatitisCbreastcancerovariancancerhypertensioninsufficientevidenceforscreening52y.o.overweight/ obesitycardiovasculardiseasetamoxifenmultidoseinitial series,then 1 doseat 2-6months≥ 100mg/dLcolorectalcancer2 doses,2-6monthsapartraloxifeneHepatitisB40-70 y.o.,ASCVD ≥10%, lowbleeding riskq1-2ymammogrambased on lifeexpectancy /health statusanxietyq3y40-75 y.o., LDL≥ 190 or DM orASCVD ≥ 20 %or ASCVD ≥5% + riskfactors50y.o.statin≥ 126mg/dL≥ 140mg/dLq2ypneumococcalFractureRiskAssessmentToolq15ydyslipidemiaTyrer-Cuzickmodel40-75 y.o.;LDL > 190 orASCVD ≥10% + ≥ 1risk factordiabetes60y.o.≥6.5%lungcancerhormonetherapy40y.o.Timedup andgo testcervicalcancerdepressionherpeszoster1 dose; 2doses (2-6monthsapart) ifimmunocomp40-75 y.o.,ASCVD ≥7.5%, ≥ 1risk factorGailmodel≥20%tobaccouse≤q2ycommunity-dwelling,postmenopausalwomen< 60y.o.q1y≥ 40 y.o.; LDL ≥190 or DM orASCVD ≥ 20 %or ASCVD ≥5% + riskfactorsaspirinq1ymammogram40-59 y.o.,ASCVD ≥10%, lowbleeding risk75y.o.≥ 200mg/dLHIVPREVENTequationq5yaromataseinhibitorsdementia65y.o.≥5.7%womenage 55-64 y.o.3%HepatitisCbreastcancerovariancancerhypertensioninsufficientevidenceforscreening52y.o.overweight/ obesitycardiovasculardiseasetamoxifenmultidoseinitial series,then 1 doseat 2-6months≥ 100mg/dLcolorectalcancer2 doses,2-6monthsapartraloxifeneHepatitisB40-70 y.o.,ASCVD ≥10%, lowbleeding riskq1-2ymammogrambased on lifeexpectancy /health statusanxietyq3y40-75 y.o., LDL≥ 190 or DM orASCVD ≥ 20 %or ASCVD ≥5% + riskfactors50y.o.statin≥ 126mg/dL≥ 140mg/dLq2ypneumococcalFractureRiskAssessmentToolq15ydyslipidemiaTyrer-Cuzickmodel40-75 y.o.;LDL > 190 orASCVD ≥10% + ≥ 1risk factordiabetes60y.o.≥6.5%lungcancerhormonetherapy40y.o.Timedup andgo testcervicalcancerdepressionherpeszoster1 dose; 2doses (2-6monthsapart) ifimmunocomp40-75 y.o.,ASCVD ≥7.5%, ≥ 1risk factorGailmodel≥20%tobaccouse≤q2ycommunity-dwelling,postmenopausalwomen< 60y.o.q1y≥ 40 y.o.; LDL ≥190 or DM orASCVD ≥ 20 %or ASCVD ≥5% + riskfactorsaspirinq1ymammogram40-59 y.o.,ASCVD ≥10%, lowbleeding risk75y.o.≥ 200mg/dLHIVPREVENTequationq5yaromataseinhibitorsdementia65y.o.≥5.7%

Untitled Bingo - Call List

(Print) Use this randomly generated list as your call list when playing the game. There is no need to say the BINGO column name. Place some kind of mark (like an X, a checkmark, a dot, tally mark, etc) on each cell as you announce it, to keep track. You can also cut out each item, place them in a bag and pull words from the bag.


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
  1. women age 55-64 y.o.
  2. 3%
  3. Hepatitis C
  4. breast cancer
  5. ovarian cancer
  6. hypertension
  7. insufficient evidence for screening
  8. 52 y.o.
  9. overweight / obesity
  10. cardiovascular disease
  11. tamoxifen
  12. multidose initial series, then 1 dose at 2-6 months
  13. ≥ 100 mg/dL
  14. colorectal cancer
  15. 2 doses, 2-6 months apart
  16. raloxifene
  17. Hepatitis B
  18. 40-70 y.o., ASCVD ≥ 10%, low bleeding risk
  19. q1-2y mammogram based on life expectancy / health status
  20. anxiety
  21. q3y
  22. 40-75 y.o., LDL ≥ 190 or DM or ASCVD ≥ 20 % or ASCVD ≥ 5% + risk factors
  23. 50 y.o.
  24. statin
  25. ≥ 126 mg/dL
  26. ≥ 140 mg/dL
  27. q2y
  28. pneumococcal
  29. Fracture Risk Assessment Tool
  30. q15y
  31. dyslipidemia
  32. Tyrer-Cuzick model
  33. 40-75 y.o.; LDL > 190 or ASCVD ≥ 10% + ≥ 1 risk factor
  34. diabetes
  35. 60 y.o.
  36. ≥ 6.5%
  37. lung cancer
  38. hormone therapy
  39. 40 y.o.
  40. Timed up and go test
  41. cervical cancer
  42. depression
  43. herpes zoster
  44. 1 dose; 2 doses (2-6 months apart) if immunocomp
  45. 40-75 y.o., ASCVD ≥ 7.5%, ≥ 1 risk factor
  46. Gail model
  47. ≥ 20%
  48. tobacco use
  49. ≤ q2y
  50. community-dwelling, postmenopausal women
  51. < 60 y.o.
  52. q1y
  53. ≥ 40 y.o.; LDL ≥ 190 or DM or ASCVD ≥ 20 % or ASCVD ≥ 5% + risk factors
  54. aspirin
  55. q1y mammogram
  56. 40-59 y.o., ASCVD ≥ 10%, low bleeding risk
  57. 75 y.o.
  58. ≥ 200 mg/dL
  59. HIV
  60. PREVENT equation
  61. q5y
  62. aromatase inhibitors
  63. dementia
  64. 65 y.o.
  65. ≥ 5.7%